Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy targeting immune-mediated inflammatory diseases. According…
Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…
A growing body of evidence suggests that GLP-1 receptor agonists, a class of medications commonly used to treat diabetes and obesity, may play an important role in managing hidradenitis suppurativa…
A recent study has brought attention to the complex challenges faced by children with hidradenitis suppurativa (HS), a chronic and often painful skin condition. According to new research summarized by…
According to a story from Healio, a recent study doesn't bode well for people living with hidradenitis suppurativa (HS), a serious and debilitating skin disease. The data found that comorbidities…
There are inequities when it comes to race in the medical sphere, just as there are in every other facet of life. One specific issue pertains to clinical trials, as…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
